Quick Answer
Immix Biopharma, Inc. reported Stockholders Equity of $13.25 million for the year ending 2024.
- Immix Biopharma, Inc. showed a decrease of -19.2% in Stockholders Equity from 2023 to 2024.
- This data is from Immix Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2025.
- XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2020: -$4.73 million | Q1 2021: -$5.71 million | Q2 2021: -$5.85 million | Q3 2021: -$6.20 million | Q4 2021: $17.99 million | Q1 2022: $19.65 million | Q2 2022: $18.11 million | Q3 2022: $16.75 million | Q1 2023: $11.77 million | Q2 2023: $13.23 million | Q3 2023: $19.77 million | Q1 2024: $27.92 million | Q2 2024: $23.89 million | Q3 2024: $17.55 million.
- Over the full 6 years of available data (2019 to 2024), Immix Biopharma, Inc.'s Stockholders Equity has grown by 463.4%.
- Historical annual values: Fiscal year 2024: $13.25 million | Fiscal year 2023: $16.41 million | Fiscal year 2022: $13.16 million | Fiscal year 2021: $17.99 million | Fiscal year 2020: -$4.73 million | Fiscal year 2019: -$3.65 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: